Effects of Low-level Laser Therapy on Global Gene Expression of Young Males Submitted to Physical Strength Training

February 3, 2013 updated by: Cleber Ferraresi, Universidade Federal de Sao Carlos
Muscle performance is largely influenced by modulations in gene expressions of muscle tissue. In this context, low-level laser therapy has been used to improve muscle performance in experimental models and human researches. Thereby, the investigators examined modulations on global gene expression of muscle tissue influenced by exercise associated to low-level laser therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study assessed muscle performance in isokinetic dynamometry and leg press device; global gene expression of muscle tissue by microarray analysis

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • São Paulo
      • São Carlos, São Paulo, Brazil, 13565-905
        • Federal University of São Carlos

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 28 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • healthy males aged between 18 and 28 years;
  • body mass index (BMI) equal to or less than 26 kg/m2;
  • moderated pattern of physical activity

Exclusion Criteria:

  • previous injury to the femoral quadriceps or hamstring muscles (within 6 months prior to study),
  • osseous or articular disorder in the lower limbs,
  • cardiovascular system disorders,
  • systemic disease, and
  • taking prescription medicines or using dietary supplements such as muscle mass builders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Low-level laser therapy and training
Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
Device: Low-level laser therapy and training
Other Names:
  • Laser
  • Low-level laser therapy
  • Laser therapy
Active Comparator: Training without low-level laser therapy
Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
Other: Training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Global gene expression by microarray analysis
Time Frame: 12 weeks
12 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Muscle performance in leg press device
Time Frame: 12 weeks
12 weeks
Muscle performance in isokinetic dynamometer
Time Frame: 12 weeks
12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunohistochemical analysis
Time Frame: 12 weeks
Immunohistochemical analysis to quantify morphology and cells of muscle tissue as satellite cells.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universidade Federal de Sao Carlos

Collaborators

Fundação de Amparo à Pesquisa do Estado de São Paulo
Faculty of Medicine of Ribeirão Preto (FMRP-USP)
Centro de Pequisas de Ótica e Fotônica
Fundação Hemocentro de Ribeirão Preto

Investigators

  • Principal Investigator: Cleber Ferraresi, MSc, Universidade Federal de Sao Carlos
  • Study Director: Nivaldo A Parizotto, PhD, Universidade Federal de Sao Carlos
  • Study Director: Vanderlei S Bagnato, PhD, University of Sao Paulo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Actual)

January 1, 2012

Study Completion (Actual)

September 1, 2012

Study Registration Dates

First Submitted

September 15, 2012

First Submitted That Met QC Criteria

February 3, 2013

First Posted (Estimate)

February 5, 2013

Study Record Updates

Last Update Posted (Estimate)

February 5, 2013

Last Update Submitted That Met QC Criteria

February 3, 2013

Last Verified

February 1, 2013

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CAAE: 0150.0.135.000-10

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe